BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided, one in five surveyed gastroenterologists, hepatologists, and infectious disease specialists reported that in the past six months, they have begun warehousing patients (e.g., intentionally delaying treatment) in anticipation of the next generation of HCV treatments--notably more physicians than six months ago, when only 6 percent reported that they had begun warehousing patients.
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )
Furthermore, only one in five physicians agrees ...
read more